Four patients, including three with the acquired immunodeficiency syndrome (AIDS), were treated with high-dose, buffy coat-derived alpha-interferon for progressive cytomegalovirus retinitis. Two of these patients had decreased viruria during therapy and the other two had increased viruria. There was evidence of progression of disease despite therapy in all patients, although the retinitis eventually became quiescent in the patient without AIDS. The severe immunosuppression encountered in AIDS patients complicates the management of cytomegalovirus and other opportunistic infections. CMV retinitis has become more commonly recognized as a complication of chronic CMV infection in immunosuppressed hosts, including those with the acquired immunodeficiency syndrome (AIDS) (5). Patients with CMV retinitis are good candidates for antivfral trials for several reasons. The disease tends to evolve less rapidly than some other CMV syndromes, thus allowing time for virological confirmation of the diagnosis before initiating therapy and time for a therapeutic effect to have an impact on the disease process. Because the eye lesions are characteristic and easily followed by objective criteria such as fundus photographs, clinical response may be readily assessed. Also, the risk of permanent visual loss and the lack of proven effective therapy has stimulated the use'of experimental antivirals in an effort to preserve vision.
Antiviral therapy of systemic cytomegalovirus (CMV)
infection remains a difficult problem. Various drugs have been used for CMV infection in uncontrolled settings, with inclusive results. Vidarabine ihay suppress viral excretion during therapy, without effect on clinical manifestations (6), or with possible clinical benefit when given in high, neartoxic doses in CMV retinitis (10) . Acyclovir was reported to have some clinical benefit in immunosuppressed hosts with CMV infection in one institution (2) , but in another study, seven of eight bone marrow transplant recipients with biopsy-proven CMV pneumonia died despite high-dose acyclovir therapy (12) . Systemic leukocyte interferon temporarily suppressed viruria in infants with congenital CMV infection (1) . Bone marrow transplant recipients with CMV pneumonia did not demonstrate clinical improvement from treatment with leukocyte interferon alone (9) or in combination with vidarabine (8) .
CMV retinitis has become more commonly recognized as a complication of chronic CMV infection in immunosuppressed hosts, including those with the acquired immunodeficiency syndrome (AIDS) (5) . Patients with CMV retinitis are good candidates for antivfral trials for several reasons. The disease tends to evolve less rapidly than some other CMV syndromes, thus allowing time for virological confirmation of the diagnosis before initiating therapy and time for a therapeutic effect to have an impact on the disease process. Because the eye lesions are characteristic and easily followed by objective criteria such as fundus photographs, clinical response may be readily assessed. Also, the risk of permanent visual loss and the lack of proven effective therapy has stimulated the use'of experimental antivirals in an effort to preserve vision.
We report here our experience in the treatment of four patients with'CMV retinitis, using high-dose human leukocyte interferon. Three of the patients had AIDS. We monitored response clinically and virologically, using traditional tissue culture methods as well as the recently developed DNA hybridization assay for rapid measurement of viruria (3 1,300/mm3 to a range of 700 to 1,000/mm3. The interferon dose was nevertheless increased to 5 x 106 U twice daily beginning 12 days after beginning therapy. This did not result in any further decrease of granulocyte counts; in fact, they rose to pretreatment levels. The patient experienced moderately severe anorexia and malaise, which appeared worse than that present before treatment. The increased interferon dosage was given for 26 days (for a total of 38 days of interferon). Four-hour post-injection interferon levels in the blood ranged from 80 U/ml at the lower dose to 225 U/ml at the higher dose. Viruria increased during treatment as measured by culture and DNA hybridization. Eye lesions gradually progressed during the treatment period. After discontinuation of treatment, the patient was not available for followup examination, but his disease resulted in total blindness, and he died 2 months later from Kaposi's sarcoma.
Case 2. A 43-year-old homosexual male was referred for interferon treatment because of a 3-week history of visual loss due to CMV retinitis. AIDS had been diagnosed 10 Virological monitoring of the patients revealed that, consistent with past experience, interferon therapy did not result in eradication of viruria. In two patients in the present study, it is possible that the decreases in viruria seen during therapy could be related to interferon, analogous to observations previously reported in congenitally infected infants (1), but it is also apparent that this is not a consistent effect since the other two patients actually had increased viruria. In one instance we also demonstrated that viremia was not eradicated after 2 weeks of high-dose interferon treatment.
In the management of CMV retinitis, the first step is to reduce or eliminate exogenous immunosuppressive therapy. When this fails or when immunosuppression is due to disease, the threat to vision and the paucity of current therapeutic options will encourage further efforts at experimental antiviral therapy. Still to be evaluated are the various highly purified and recombinant DNA-derived interferons, which could have biological properties different from those of the buffy coat-derived material we used in this study. Newer nucleoside analogs with greater in vitro activity against CMV than the agents currently in clinical use should be available for experimental use in the near future. As before, close virological monitoring will be a necessary adjunct to clinical studies, since a virological response should precede any beneficial impact on clinical disease.
